David T. Hung's most recent trade in Nuvation Bio Inc - Ordinary Shares - Class A was a trade of 500,000 Class A Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvation Bio Inc (Class A) | David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 16 Jun 2025 | 500,000 | 59,281,054 | - | 1.8 | 893,500 | Class A Common Stock |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 16,697 | 16,697 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 11,215 | 23,410 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | David T. Hung | Director | Sale of securities on an exchange or to another person at price $ 17.30 per share. | 03 Jun 2025 | 999 | 12,195 (0%) | 0% | 17.3 | 17,280 | Ordinary Shares |
| Nuvation Bio Inc (Class A) | David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.62 per share. | 04 Apr 2025 | 300,000 | 58,781,054 | - | 1.6 | 487,500 | Class A Common Stock |
| Nuvation Bio Inc (Class A) | David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.66 per share. | 04 Apr 2025 | 200,000 | 58,481,054 | - | 1.7 | 332,720 | Class A Common Stock |
| Nuvation Bio Inc (Class A) | David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,229 | 6,229 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,053 | 13,194 | - | 0 | Restricted Stock Units | |
| Nuvation Bio Inc (Class A) | David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,554 | 12,554 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 4,350 | 4,350 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 2,427 | 9,141 | - | 0 | Restricted Stock Units | |
| Nuvation Bio Inc (Class A) | David T. Hung | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 1,499 | 1,499 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | David T. Hung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 814 | 6,714 | - | 0 | Restricted Stock Units |